Related Experiment Video

Updated: Apr 21, 2026

Performing and Processing FNA of Anterior Fat Pad for Amyloid
09:41

Performing and Processing FNA of Anterior Fat Pad for Amyloid

Published on: October 30, 2010

56.1K

[Progress in the diagnosis and treatment of cardiac amyloidosis]

Artur Jurczyszyn, Anna Engel, Marek Rajzer

    Przeglad Lekarski
    |October 28, 2014
    PubMed

    Insights

    Cardiac amyloidosis, a heart condition, is often diagnosed late. Treatment and prognosis vary by amyloid protein type, with advances in imaging and proteomics offering hope for better outcomes.

    Area of Science:

    • Cardiology and amyloidosis research.
    • Focus on cardiac manifestations of amyloidosis.

    Context:

    • Cardiac amyloidosis is a significant cause of mortality.
    • Late diagnosis due to nonspecific symptoms and subtle imaging signs hinders timely intervention.
    • Treatment strategies are protein-type dependent.

    Purpose:

    • To review current understanding and treatment of cardiac amyloidosis.
    • To highlight diagnostic challenges and emerging therapeutic approaches.
    • To discuss the impact of amyloid protein type on prognosis.

    Summary:

    • Amyloidosis affects the heart, leading to cardiomyopathy and mortality.
    • Treatment varies: systemic chemotherapy for immunoglobulin light chain amyloidosis, liver transplantation for familial transthyretin amyloidosis.
    • Emerging therapies include siRNA and protein stabilizers, with ongoing clinical trials.
    • Prognosis is poorer for light chain amyloidosis compared to other types.

    Impact:

    • Advances in cardiac imaging and proteomics are crucial for improved diagnosis, prognosis, and treatment of cardiac amyloidosis.
    • Enhanced diagnostic capabilities can lead to earlier intervention and better patient outcomes.
    • Personalized treatment approaches based on amyloid protein type are essential.

    More Related Videos

    Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis06:33

    Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

    Published on: June 9, 2018

    7.2K
    Transthoracic Echocardiographic Examination in the Rabbit Model14:46

    Transthoracic Echocardiographic Examination in the Rabbit Model

    Published on: June 1, 2019

    12.6K

    Related Concept Videos

    Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

    Cardiomyopathy IV: Restrictive Cardiomyopathy

    Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
    930
    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    742
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    766
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    789
    Myocarditis III: Medical Management01:14

    Myocarditis III: Medical Management

    Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
    340
    Acute Coronary Syndrome III: Diagnostic Studies01:30

    Acute Coronary Syndrome III: Diagnostic Studies

    Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
    490